Replies to post #83882 on Biotech Values

[genisi]

AMGN’s D-mab in BC trial - more data:
The median time to first on-study SRE was not reached for denosumab (meaning it is >34 months) and was 26.5 months for Zometa.

http://wwwext.amgen.com/media/media_pr_detail.jsp?year=2009&releaseID=1334123